{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:04:24Z","timestamp":1789790664903,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.044","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:36:33Z","timestamp":1787927793000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adaptive Bridging and Holding Therapy Frequently Reduces Tumor Burden and Is Associated With Reduced Toxicity After CAR-T Cell Therapy in Multiple Myeloma: A Single-Center Real-World Experience"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9235-4078","authenticated-orcid":false,"given":"Jule Cecilia","family":"Artzenroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Al-Bazaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Bartke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Cords","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4623-2948","authenticated-orcid":false,"given":"Corinna","family":"G\u00fcsmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Harzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2922-4863","authenticated-orcid":false,"given":"Fabian","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Kamili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Leypoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Madanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte Benedikt","family":"Monin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-5105","authenticated-orcid":false,"given":"Christoph","family":"Schaefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0192-2434","authenticated-orcid":false,"given":"Johan","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Alsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jtct.2026.08.044_bib0001","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.044_bib0002","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.jtct.2026.08.044_bib0003","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.044_bib0004","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jtct.2026.08.044_bib0005","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.044_bib0006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.044_bib0007","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.044_bib0008","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jtct.2026.08.044_bib0009","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.08.044_bib0010","unstructured":"Bristol Myers Squibb. ABECMA (idecabtagene vicleucel) suspension for intravenous infusion: prescribing information. U.S. Food and Drug Administration 2025. https:\/\/www.fda.gov\/media\/147055\/download. Accessed August 16, 2026."},{"key":"10.1016\/j.jtct.2026.08.044_bib0011","unstructured":"Janssen Biotech, Inc. CARVYKTI (ciltacabtagene autoleucel) suspension for intravenous infusion: prescribing information. U.S. Food and Drug Administration; 2025. https:\/\/www.fda.gov\/media\/156560\/download. Accessed August 16, 2026."},{"issue":"4","key":"10.1016\/j.jtct.2026.08.044_bib0012","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.044_bib0013","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.044_bib0014","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.044_bib0015","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.044_bib0016","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-025-01441-3","article-title":"Clinical course, risk factors and mitigating strategies for immune effector cell-associated late-onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma","volume":"16","author":"Lim","year":"2026","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.044_bib0017","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.044_bib0018","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.08.044_bib0019","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. U.S. Department of Health and Human Services; 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed August 16, 2026."},{"issue":"224","key":"10.1016\/j.jtct.2026.08.044_bib0020","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.044_bib0021","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"15","key":"10.1016\/j.jtct.2026.08.044_bib0022","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood.2024024965","article-title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes","volume":"145","author":"Freeman","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.044_bib0023","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2026.08.044_bib0024","article-title":"Effectiveness of bridging therapy corresponds to improved outcomes after receiving CAR-T therapy: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma","volume":"24","author":"Lin","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.044_bib0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.044_bib0026","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.044_bib0027","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.044_bib0028","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.044_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2026.08.044_bib0030","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2025-2215","article-title":"Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma","volume":"146","author":"Dhakal","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.044_bib0031","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA-directed CAR T-cell therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.044_bib0032","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","article-title":"Autologous stem cell boost improves persistent immune effector cell-associated hematotoxicity following BCMA-directed chimeric antigen receptor (CAR) T cell therapy in multiple myeloma","volume":"59","author":"Mohan","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.044_bib0033","article-title":"Safety and efficacy of ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma: a CIBMTR study","author":"Hansen","year":"2026","journal-title":"Blood Cancer J"},{"issue":"10292","key":"10.1016\/j.jtct.2026.08.044_bib0034","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2026.08.044_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2026.02.062","article-title":"Impact of intensive cyclophosphamide-containing multi-agent bridging therapy on outcomes after idecabtagene vicleucel in multiple myeloma","author":"Kikuchi","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.044_bib0036","doi-asserted-by":"crossref","first-page":"504.e1","DOI":"10.1016\/j.jtct.2023.05.016","article-title":"Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma","volume":"29","author":"Zafar","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.044_bib0037","first-page":"3065","article-title":"Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma","volume":"110","author":"Portuguese","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.044_bib0038","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-025-01330-9","article-title":"Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement","volume":"15","author":"Steinhardt","year":"2025","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.jtct.2026.08.044_bib0039","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.2025029773","article-title":"Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy","volume":"146","author":"Dhakal","year":"2025","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2026.08.044_bib0040","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.044_bib0041","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.044_bib0042","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","article-title":"Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network","volume":"12","author":"van de Donk","year":"2025","journal-title":"Lancet Haematol"},{"issue":"817","key":"10.1016\/j.jtct.2026.08.044_bib0043","article-title":"CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis","volume":"17","author":"Ben Khelil","year":"2025","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.jtct.2026.08.044_bib0044","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.044_bib0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2026.08.044_bib0046","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2024-208376","article-title":"Pre-apheresis prediction of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"144","author":"Rejeski","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.044_bib0047","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41409-025-02612-3","volume":"60","author":"Goel","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.jtct.2026.08.044_bib0048","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma (MyCARe)","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.044_bib0049","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/bloodadvances.2024015008","article-title":"Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis","volume":"9","author":"Richardson","year":"2025","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.jtct.2026.08.044_bib0050","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/bloodadvances.2024015732","article-title":"Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR T-cell therapy for multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:38:43Z","timestamp":1789789123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"alternative-id":["S2666636726006858"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.044","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adaptive Bridging and Holding Therapy Frequently Reduces Tumor Burden and Is Associated With Reduced Toxicity After CAR-T Cell Therapy in Multiple Myeloma: A Single-Center Real-World Experience","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}